Market Overview

UPDATE: ISI Group Reiterates Buy Rating, Raises PT on ICON plc on Solid 4Q Results

Related ICLR
Top 4 Mid-Cap Stocks In The Medical Laboratories & Research Industry With The Lowest PEG Ratio
ICON Is Now A Strong Buy: Should It Be In Your Portfolio?

In a report published Wednesday, ISI Group reiterated its Buy rating on ICON plc (NASDAQ: ICLR), and slightly raised its price target from $32.00 to $33.00.

ISI Group noted, “ICON posted solid 4Q results, including net bookings of $378 MM and book-to-bill of 1.26x (vs. ISIe of $344MM and 1.16x), providing improved visibility on the revenue trajectory going forward. Revenue growth of 23.7% during 4Q was driven by the conversion of recent strong bookings as well as an increased contribution from ICLR's strategic partnership with Pfizer. Gross margins and operating margins both increased sequentially and year-over-year as central lab continues to improve and clinical research saw healthy margin pull-through. In addition, ICLR also raised its FY13 guidance, which now includes revenue of $1.275 Bn and EPS of $1.52 at the mid-point. The strong 4Q results and the increased FY13 guidance make us increasingly confident in ICLR's ability to execute on its strategy and create shareholder value.”

ICON plc closed on Tuesday at $28.73.

Latest Ratings for ICLR

DateFirmActionFromTo
Oct 2014ISI GroupDowngradesStrong BuyNeutral
Aug 2014Credit SuisseMaintainsOutperform
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for ICLR
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (ICLR)

Around the Web, We're Loving...

Get Benzinga's Newsletters